Iris R. Joosse

Mrs. Iris R. Joosse

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2022 in Health Policy
Verified
Journal Article
Open access
IJIris R. Joosse
Iris R. Joosse
DTDavid Tordrup
David Tordrup
JGJulie Glanville
Julie Glanville
EKEleanor Kotas
Eleanor Kotas
AMAukje Mantel
Aukje Mantel
HHHendrika A. Van den Ham
Hendrika A. Van den Ham
• Research on policies promoting price transparency is scarce and (partially) inconclusive. • Public disclosure of medicine prices could be effective in reducing prices. • More robust evidence is needed to confirm the effects of these policies. • Future research should also focus on unintended effects of these policies.

27 November 2025 in BMJ Global Health
Verified
Journal Article
Open access
IJIris R. Joosse
Iris R. Joosse
AMAukje Mantel
Aukje Mantel
HHHendrika A. Van den Ham
Hendrika A. Van den Ham
LALourdes Cantarero Arevalo
Lourdes Cantarero Arevalo
Introduction: Given the critical role of medicines in reducing the burden of non-communicable diseases (NCDs), we analysed factors that hinder the availability of quality medicines for managing NCDs at the point of service delivery, with a particular focus on low-income and middle-income countries. Methods: In this scoping review, literature published in PubMed, Embase, Web of Science, the World Bank eLibrary and the WHO’s Institutional Repository for Information Sharing (WHO IRIS) was collected (January 2009–May 2025). Literature was excluded if it did not specifically address NCD medicines, discussed global rather than national determinants of availability only, failed to detail supply chain inefficiencies or exclusively reported on other dimensions of access (ie, pricing/affordability, trial access, regulatory access). From cross-sectional assessments of medicine availability, mean availability was extracted, and from quantitative, interventional studies, details on the intervention and its effectiveness on NCD medicine availability were extracted. From the remaining studies, descriptions of barriers and recommendations or empirically proven interventions to improve availability were extracted and mapped according to the pharmaceutical value chain (PVC). Results: Our review of 3348 records identified 83 eligible studies. The mean availability of NCD medicines reported in cross-sectional surveys was suboptimal (<80%) in 39 of 46 surveyed countries. We found barriers to available NCD medicines across all components of the PVC. Deficiencies in governance, financing, the health workforce, health information systems and service delivery underscore the interlinkage of various health system building blocks and stakeholders in determining availability. Nonetheless, most barriers pertained to supply chain inefficiencies, followed by challenges in regulatory systems and quality monitoring. Conclusions: The evidence highlights the need for political commitment to NCDs, broad stakeholder involvement, integrated stock management systems and increased human resources to make NCD medicines more available to patients worldwide.

27 September 2023 in Health Policy
Verified
Journal Article
Open access
IJIris R. Joosse
Iris R. Joosse
DTDavid Tordrup
David Tordrup
JGJulie Glanville
Julie Glanville
AMAukje Mantel
Aukje Mantel
HHHendrika A. Van den Ham
Hendrika A. Van den Ham
The regulation of mark-ups throughout the pharmaceutical supply and distribution chain may be a valuable approach to control prices of medicines and to achieve broader access to medicines. As part of a wider review, we aimed to systematically determine whether policies regulating mark-ups are effective in managing the prices of pharmaceutical products. We searched for studies published between January 1, 2004 and October 10, 2019, comparing policies on regulating mark-ups against other interventions or a counterfactual. Eligible study designs included randomized trials, and non-randomized or quasi-experimental studies such as interrupted time-series (ITS), repeated measures (RM), and controlled before-after studies. Studies were eligible if they included at least one of the following outcomes: price (or expenditure as a proxy for price and volume), volume, availability or affordability of pharmaceutical products. The quality of the evidence was assessed using the GRADE methodology. A total of 32,011 records were retrieved, seven of which were eligible for inclusion for this review. The limited body of evidence cautiously suggests that policies regulating mark-ups may be effective in reducing medicine prices and pharmaceutical expenditures. However, the design of mark-up regulations is a critical factor for their potential success. Additional research is required to confirm the effects of these policies on the availability, affordability or usage patterns of medicines and in low- and middle-income countries.

20 September 2023 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
IJIris R. Joosse
Iris R. Joosse
HHHendrika A. Van den Ham
Hendrika A. Van den Ham
AMAukje K Mantel-Teeuwisse
Aukje K Mantel-Teeuwisse
FSFatima Suleman
Fatima Suleman
Introduction The effectiveness of a health system in providing access to medicines is in part determined by the alignment of several core pharmaceutical processes. For South Africa’s public health sector, these include the registration of medicines, selection and subsequent procurement through national tenders. Registration, selection and reimbursement are key processes in the private sector. This study assessed the alignment of forementioned processes for essential paediatric oncology medicines in South Africa. Methods A selection of priority chemotherapeutics, antiemetics and analgesics in the treatment of five prevalent childhood cancers in South Africa was compared with those listed in 1) the WHO Essential Medicines List for Children (WHO EMLc) 2021, 2) the registered health products database of South Africa, 3) the relevant South African National Essential Medicines Lists (NEML), 4) bid packs and awarded tenders for oncology medicines for 2020 and 2022 and 5) oncology formularies from the leading Independent Clinical Oncology Network (ICON) and two private sector medical aid schemes. Consistency between these sources was assessed descriptively. Results There was full alignment for 25 priority chemotherapeutics for children between the NEML, the products registered in South Africa and those included on tender. Due to unsuccessful procurement, access to seven chemotherapeutics was potentially constrained. For antiemetics and analgesics, eight of nine active ingredients included on the WHO EMLc were also registered in South Africa and on its NEML. An exploratory assessment of private sector formularies showed many gaps in ICON’s formulary and two medical scheme formularies (listing 33% and 24% of the chemotherapeutics, respectively). Conclusion Despite good alignment in public sector pharmaceutical processes, access constraints to essential chemotherapeutics for children may stem from unsuccessful tenders. Private sector formularies show major gaps; however, it is unclear how this translates to access in clinical practice.

13 March 2022 in Health Policy
Verified
Journal Article
Open access
IJIris R. Joosse
Iris R. Joosse
DTDavid Tordrup
David Tordrup
LBLisa Bero
Lisa Bero
AMAukje Mantel
Aukje Mantel
HHHendrika A. Van den Ham
Hendrika A. Van den Ham
Robust evidence from health policy research has the potential to inform policy-making, but studies have suggested that methodological shortcomings are abundant. We aimed to identify common methodological weaknesses in pharmaceutical pricing policy analyses. A systematic review (SR) of studies examining pharmaceutical pricing policies served as basis for the present analysis. We selected all studies that were included in the SR (n = 56), and those that were excluded from the SR due to ineligible study designs only (n = 101). Risk of bias was assessed and specific study design issues were recorded to identify recurrent methodological issues. Sixty-one percent of studies with a study design eligible for the SR presented with a high risk of bias in at least one domain. Potential interference of co-interventions was a source of possible bias in 53% of interrupted time series studies. Failing to consider potential confounders was the primary cause for potential bias in difference-in-differences, regression, and panel data analyses. In 101 studies with a study design not eligible for the SR, 32% were uncontrolled before-after studies and 23% were studies without pre-intervention data. Some of the methodological issues encountered may be resolved during the design of a study. Awareness among researchers on methodological issues will help improve the rigor of health policy research in general.

29 February 2024 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
IJIris R. Joosse
Iris R. Joosse
HHHendrika A. Van den Ham
Hendrika A. Van den Ham
AMAukje Mantel
Aukje Mantel
FSFatima Suleman
Fatima Suleman
This study explored the treatment-related, financial and psychological experiences of caregivers during cancer treatment of their children in South Africa’s (SA) public and private sectors. In this exploratory study, three focus groups were conducted with caregivers of children undergoing cancer treatment in SA’s public healthcare sector. A fourth small focus group with two parents in the private sector was conducted online. A mixed-methods approach was employed using a combination of thematic analysis and grounded theory. Of the 20 public sector caregivers, many expressed frustration at the number of visits to primary healthcare clinics before being referred. Caregivers had difficulties coping with and accepting the diagnosis, alongside managing continued care for the child and other children at home. Support received by family and community members was varied. Financial strain was an important concern. The two private sector parents indicated greater levels of support and no financial hardship, but expressed similar levels of emotional stress. These caregiver experiences indicate that improvements are urgently needed in the recognition of childhood cancer symptoms at primary healthcare level in SA. They also highlight a need for increased financial support from government through social grants, travel allowances and nutritional support.